Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Giagulli, Cinzia ^a   Marsico, Stefania ^b   Magiera, Anna K ^c   Bruno, Rosalinda ^b   Caccuri, Francesca ^a   Barone, Ines ^b   Fiorentini, Simona ^a   Andò, Sebastiano ^b   Caruso, Arnaldo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

^c Medestea Research   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P17; PROTEIN P17 RECEPTOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; P17 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1; PTEN PROTEIN, HUMAN; VIRUS RECEPTOR;

ARTICLE; B LYMPHOCYTE; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IONIC STRENGTH; MALIGNANT TRANSFORMATION; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RAJI CELL; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; VIRUS STRAIN; WESTERN BLOTTING; AMINO ACID SEQUENCE; CELL CULTURE; CHEMISTRY; CLONOGENIC ASSAY; ENZYMOLOGY; METABOLISM; MOLECULAR GENETICS; OSMOLARITY; PATHOLOGY; PHOSPHORYLATION; PROTEIN QUATERNARY STRUCTURE; SEQUENCE ALIGNMENT; SOLUTION AND SOLUBILITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; OSMOLAR CONCENTRATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, VIRUS; RHO-ASSOCIATED KINASES; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SOLUTIONS; TRANSCRIPTION FACTOR AP-1;

EID: 79952655225     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017831     Document Type: Article

References (58)

1. Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, et al. (1994) Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J Mol Biol 244: 198-223.
2. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI, (1996) Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci USA 93: 3099-3104.
3. Verli H, Calazans A, Brindeiro R, Tanuri A, Guimarães JA, (2007) Molecular dynamics analysis of HIV-1 matrix protein: clarifying differences between crystallographic and solution structures. J Mol Graph Model 26: 62-68.
4. Freed EO, Orenstein JM, Buckler-White AJ, Martin MA, (1994) Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol 68: 5311-5320.
5. Bukrinskaya AG, Ghorpade A, Heinzinger NK, Smithgall TE, Lewis RE, et al. (1996) Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc Natl Acad Sci U S A 93: 367-371.
6. Ehrlich L, Fong S, Scarlata S, Zybarth G, Carter C, (1996) Partitioning of HIV-1 Gag and Gag-related proteins to membranes. Biochemistry 35: 3933-3943.
7. Haffar OK, Popov S, Dubrovsky L, Agostini I, Tang H, et al. (2000) Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. J Mol Biol 299: 359-368.
8. Fiorentini S, Marini E, Caracciolo S, Caruso A, (2006) Functions of the HIV-1 matrix protein p17. New Microbiol 29: 1-10.
9. Gould SJ, Booth AM, Hildreth JE, (2003) The Trojan exosome hypothesis. Proc Natl Acad Sci USA 100: 10592-10597.
10. Nickel W, (2003) The mystery of nonclassical protein secretion: A current view on cargo proteins and potential export routes. Eur J Biochem 270: 2109-2119.
11. Dong X, Li H, Derdowski A, Ding L, Burnett A, Chen X, et al. (2005) AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell 120: 663-674.
12. Fiorentini S, Riboldi E, Facchetti F, Avolio M, Fabbri M, et al. (2008) HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci U S A 105: 3867-3872.
13. Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, et al. (2005) Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 102: 14807-14812.
14. Budka H, (1990) Human immunodeficiency virus (HIV) envelope and core proteins in CNS tissues of patients with the acquired immune deficiency syndrome (AIDS). Acta Neuropathol 79: 611-619.
15. Reuse S, Calao M, Kabeya K, Guiguen A, Gatot JS, et al. (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE 4: e6093.
16. Vandergeeten C, Quivy V, Moutschen M, Van Lint C, Piette J, et al. (2007) HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha+TSA. Biochem Pharmacol 73: 1738-1748.
17. De Francesco MA, Caruso A, Fallacara F, Canaris AD, Dima F, et al. (1998) HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor. AIDS 12: 245-252.
18. De Francesco MA, Baronio M, Fiorentini S, Signorini C, Bonfanti C, et al. (2002) HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci USA 99: 9972-9977.
19. Vitale M, Caruso A, De Francesco MA, Rodella L, Bozzo L, et al. (2003) HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines. Br J Haematol 120: 337-343.
20. Marini E, Tiberio L, Caracciolo S, Tosti G, Guzman CA, et al. (2008) HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1. Cell Microbiol 10: 655-666.
21. Massiah MA, Worthylake D, Christensen AM, Sundquist WI, Hill CP, et al. (1996) Comparison of the NMR and X-ray structures of the HIV-1 matrix protein: evidence for conformational changes during viral assembly. Protein Sci 5: 2391-2398.
22. Li Z, Dong X, Wang Z, Liu W, Deng N, et al. (2005) Regulation of PTEN by Rho small GTPases. Nat Cell Biol 7: 399-404.
23. Meili R, Sasaki AT, Firtel RA, (2005) Rho Rocks PTEN. Nat Cell Biol 7: 334-335.
24. Sanchez T, Thangada S, Wu MT, Kontos CD, Wu D, (2005) PTEN as an effector in the signalling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci U S A 102: 4312-4317.
25. Jiang BH, Liu LZ, (2008) PI3K/PTEN signalling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784: 150-158.
26. Fiorentini S, Marsico S, Becker PD, Iaria ML, Bruno R, et al. (2008) Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17. Vaccine 26: 4758-4765.
27. Papsidero LD, Sheu M, Ruscetti FW, (1989) Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J Virol 63: 267-272.
28. Angel P, Karin M, (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072: 129-157.
29. Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, et al. (2009) The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 4: 761-767.
30. Shin S, Asano T, Yao Y, Zhang R, Claret FX, et al. (2009) Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism. Mol Cancer Res 7: 745-754.
31. Seger R, Krebs EG, (1995) The MAPK signalling cascade. FASEB J 9: 726-735.
32. Cantley LC, Neel BG, (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 96: 4240-4245.
33. Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP, (2008) Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 27: 5464-5476.
34. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR, (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20: 5010-5018.
35. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, et al. (2001) Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276: 48627-48630.
36. Adey NB, Huang L, Ormonde PA, Baumgard ML, Pero R, et al. (2000) Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res 60: 35-37.
37. Gericke A, Munson M, Ross AH, (2006) Regulation of the PTEN phosphatase. Gene 374: 1-9.
38. Riento K, Ridley AJ, (2003) Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4: 446-456.
39. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, et al. (2000) Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 57: 976-983.
40. Narumiya S, Ishizaki T, Uehata M, (2000) Use and properties of ROCK-specific inhibitor Y-27632. Methods Enzymol 325: 273-284.
41. Li L, Ittmann MM, Ayala G, Tsai M-J, Amato RJ, et al. (2005) The emering role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 8: 108-118.
42. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, et al. (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279.
43. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF, (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198.
44. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL, (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95: 15587-15591.
45. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
46. Backman S, Stambolic V, Mak T, (2002) PTEN function in mammalian cell size regulation. Curr Opin Neurobiol 12: 516-522.
47. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
48. Miller SJ, Lou DY, Seldin DC, Lane WS, Neel BG, (2002) Direct identification of PTEN phosphorylation sites. FEBS Lett 528: 145-153.
49. Torres J, Pulido R, (2001) The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem 276: 993-998.
50. Das S, Dixon JE, Cho W, (2003) Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci U S A 100: 7491-7496.
51. Gucalp A, Noy A, (2009) Spectrum of HIV lymphoma. Curr Opin Hematol 17: 362-367.
52. Thomas CC, Deak M, Alessi DR, van Aalten DM, (2002) High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol 12: 1256-1262.
53. Kozikowski AP, Sun H, Brognard J, Dennis PA, (2003) Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. J Am Chem Soc 125: 1144-1145.
54. Haffar O, Dubrovsky L, Lowe R, Berro R, Kashanchi F, et al. (2005) Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein. J Virol 79: 13028-13036.
55. Fiorentini S, Giagulli C, Caccuri F, Magiera AK, Caruso A, (2010) HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacol Ther 128: 433-44.
56. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, et al. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277-284.
57. Tiberio GA, Tiberio L, Benetti A, Cervi E, Pandolfo G, et al. (2007) Interleukin-6 sustains hepatic regeneration in cirrhotic rat. Hepatogastroenterology 54: 878-883.
58. Tiberio L, Tiberio GA, Bardella L, Cervi E, Cerea K, et al. (2006) Mechanisms of interleukin-6 protection against ischemia-reperfusion injury in rat liver. Cytokine 34: 131-142.